Inotuzumab ozogamicin
| Product Overview | |
| Generic Name | Inotuzumab ozogamicin |
| Brand Name(s) | Besponsa® |
| Form | Lyophilized powder for concentrate for solution for intravenous infusion |
| Strength | 1 mg per vial |
| Therapeutic Class | Antibody–drug conjugate (ADC), anti-CD22 monoclonal antibody conjugated to calicheamicin |
| ATC Code | L01XC18 |
| Manufacturing & Regulatory | |
| Manufacturer | Pfizer |
| Country | USA |
| GMP Compliance | WHO-GMP |
| Free Sale Certificate | Available per batch upon request |
| Logistics & Export | |
| Shelf Life | 36 months |
| Storage | Refrigerated (2–8 °C) |
| Incoterms | EXW/FOB/CIF negotiable |
| Lead Time | 7 - 10 Business Days |
| Documentation | |
| Certificate of Analysis (COA) | Supplied per batch upon request |
Description
Inotuzumab ozogamicin is an anti-CD22 antibody–drug conjugate indicated for the treatment of adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (B-ALL), including patients proceeding to subsequent hematopoietic stem-cell transplantation,
